skip to Main Content

Special Report: XORTX Therapeutics Inc. (NASDAQ: XRTX / TSXV: XRTX)

We are pleased to bring investors a new, special report by The Venture Letter™ venture stock newsletter on XORTX Therapeutics Inc. (NASDAQ & TSXV: XRTX) at the following link TVL – Special Report – XORTX Therapeutics Inc. – 0224.

We are excited by the prospects for XORTX and the company’s efforts to provide new and much-needed orphan drug therapy to slow progressive kidney disease. We invite investors to read our special report and take a close look at XORTX Therapeutics, now approaching its third and most important FDA drug trial.

Biotech stocks are in a bull market right now and we see XRTX as a perfect company to investigate.

Good luck and good hunting.


#theventureletter #stocksinfocus #XORTX #biotech #biotechs #biotechstocks #XBI #nasdaqlisted #stocks #


Gain insight into venture stocks & venture stock markets that only career professionals and seasoned veterans can provide.

Learn from some of the best who have learned what positives and challenges publicly-traded, venture companies can experience.

Sign up now for FREE with The Venture Letter!

"*" indicates required fields

Back To Top